RYTM Q3 2021 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$806,00078.4% margin

Operating Income

-$44M-4303.5% margin

Net Income

-$35M-3415.1% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+275.2%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$356M

Total Liabilities

$34M

Stockholders' Equity

$322M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$806,000	$0	—
Operating Income	-$44M	-$34M	-29.0%
Net Income	-$35M	-$34M	-3.8%